High-dose chemotherapy as salvage treatment for germ cell tumors. The ongoing IT94 study

Bone Marrow Transplantation

Volumn 18, Issue SUPPL. 1, 1996, Pages

  Pico, J L ^a   Castagna, L ^a   Kramar, A ^a   Biron, P ^a   Bouzy, J ^a   Rosti, G ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; TUMOR MARKER; VINBLASTINE;

AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD TOXICITY; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; GERM CELL TUMOR; HEMATOPOIETIC STEM CELL; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; PRIORITY JOURNAL; PROGNOSIS; SEMINOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; GERMINOMA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; SALVAGE THERAPY; TESTICULAR NEOPLASMS; TRANSPLANTATION, AUTOLOGOUS;

EID: 0029910728     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (31)

1. SCHMOLL, H.J. Management of early stages of testicular carcinoma: The Current Satus in Malignancies of the Genitourinary Tract. Recent Results in Cancer Research. R. Ackermann and V. Diehl (eds). Springer-Verlag, vol 126, p. 237-255, 1993.
2. BIRCH, R., WILLIAMS, S., CONE, A., et al. Prognostic factors for favorable outcome in disseminated germ cell tumors. J. Clin. Oncol. 4: 400-407, 1986.
3. BOSL, G.J., GELLER, N.L., CIRRINCIONE, C., et al. Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res. 43: 3403-3407, 1983.
4. DROZ, J.P., KRAMAR, A., GHOSN, M., et al. Prognostic factors in advanced non seminomatous testicular cancer. A multivariate logistic regression analysis. Cancer 62: 564-568, 1988.
5. NICHOLS, C.R., WILLIAMS, S.D., LOEHRER, P.J., et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Group study and Southwest Oncology Group protocol. J. Clin.Oncol. 9: 1163-1172, 1991.
6. LOEHRER, P.J., LAVER, R., ROTH, B.J., WILLIAMS, S.D., KALASINKI, L.A., EINHORN, L.H. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastin or etoposide. Ann. Int. Med. 109: 540-546, 1988.
7. NICHOLS, C.R., ROSTI G. Dose-Intensity therapy for germ cell neoplasms. Seminars in Oncology, 19 (1), suppl 2: 145-149, 1992.
8. HORWICH, A., WILSON, C., CORNES, P., GILDERSLEVE, J., DEARNALEY, D. Increasing the dose-intensity of chemotherapy in poor prognosis metastatic non-seminoma. Eur. Urol, 23: 219-223, 1993.
9. WOLFF, S.N., FER, M.F., McKAY, C.M., HANDE, K.R., HAINSWORTH, J.D., GRECO, F.A. High-dose VP 16-213 and autologous bone marrow transplantation for refractory malignancies: a phase I study. J. Clin. Oncol. 1: 701-705, 1983.
10. POSTMUS, P.E., de VRIES, E.G.E., de VRIES-HOSPERS, H.G., et al. Cyclophosphamide and VP16-213 with autologous bone marrow transplantation. A dose escalation study. Eur. J. Cancer Clin. Oncol. 20: 777-782, 1984.
11. BUCKNER, D.D., CLIFT, R.A., FEFER, A., et al. High dose cyclophosphamide for the treatment of metastatic testicular neoplasms. Cancer Chemother. Rep. 58: 709-714, 1974.
12. WHEELER, B.M., LOEHRER, P.J., WILLIAMS, S.D., EINHORN, L.H., Ifosfamide in refractory male germ cell tumors. J. Clin. Oncol. 4: 28-34, 1986.
13. OZOLS, R.F., IHDE, D.C., LINCHAN M., et al. A randomized trial of standard chemotherapy v a high dose chemotherapy regimen in the treatment of poor prognosis non seminomatous germ cell tumors. J. Clin. Oncol. 6 (6): 1031-1040, 1993.
14. SHEA, T.C., FLAHERTY, M., ELIAS, A., et al. A phase I clinical and pharmacokinetic study of Carboplatin and autologous bone marrow support. J. Clin. Oncol. 7 651-661, 1989.
15. CALVERT, A.H., NEWEL, D.R., GUMBRELL, L.A., et al. Carboplatin dosase: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol. 7: 1748-1756, 1989.
16. O'REILLY, S.M., SAMSON, D., NEWLANDS, E.S., GUIMARAES, A., RUSTIN, G.J.S., HARLAND, S.J., HARPER, PQ.G., KANEER, E.T. and MCCARTHY, D. Use of a simple formula to adjust carboplatin dose for renal function in patients receiving high dose chemotherapy and autologous bone marrow transplant for refractory or relapsed germ cell tumours. Personal communication.
17. CANETTA, R., ROZENCWEIG, M., CARTER, S.K. Carboplatin: the clinical spectrum to date. Cancer Treat. Rev. 12 (Suppl A): 125-136, 1985.
18. DROZ, J.P., PICO, J.L., GHOSN, M., et al. Long-term survivors after salvage high-dose chemotherapy with bone-marrow rescue in refractory germ cell cancer. Eur. J. Cancer 27: 831-835, 1991.
19. NlCHOLS, C.R., ANDERSEN, H.M., LAZARUS, H.M., et al. High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol. J. Clin.Oncol. 10, 1992.
20. IBRAHIM, A., ZAMBON, E., BOURHIS, H.H., et al. High-dose chemotherapy with Etoposide, Cyclophosphamide and escalating dose of Carboplatin followed by autologous bone marrow transplantation in cancer patients. A pilot study. Eur. J. Cancer, 29A: 1398-1403, 1993.
21. MOTZER, R.J., GULATI, S.C., CROWN, J., et al. High-dose chemotherapy and autologous bone-marrow rescue for patients with refractory germ cell tumors. Early intervention is better tolerated. Cancer 69: 550-556, 1992.
22. SIEGERT, W., BEYER, J., WEISSBACH, V., et al. High-dose carboplatin, etoposide and ifosfamide with autologous stem cell rescue for relapsed and refractory non-seminomatous germ cell tumors (Abst). Proc. Am. Soc. Clin. Oncol., 10: 163, 1991.
23. LOTZ, J.P., MACHOVER, D., MALASSAGNE, B., et al. Phase I-II study of two consecutive courses of high-dose epipodophyllotoxin, ifosfamide, and carboplatin with autologous bone marrow transplantation for treatment of adult patients with solid tumors. J. Clin. Oncol. 9:1860-1870, 1991.
24. LINKESCH, W., GREINIX, H.T., HOCKER, P., KRAINER, M., WAGNER, A. Long-term follow up of phase I/II trial of ultra-high carboplatin VP16, cyclophosphamide with ABMT in refractory or relapsed NSGCT. Proc. Am. Soc. Clin. Oncol., 12: 717, 1993.
25. PlCO, J.L., BIRON, P., KRAMAR, A., BOUZY, J., ROSTl, G. Update of the EBMT IT94 protocol (Germ Cell) Solid Tumors Working Party. Study presentation 22nd Annual Meeting of the European Group for Blood and Marrow Transplantation. Vienna. March 6, 1996.
26. MOTZER, R.J., GULATI, S.C., MAZUMDAR, M., et al. Phase II trial of VAB6 + high dose carboplatin + etoposide with autologous bone marrow transplantation for poor risk germ cell tumor patients. Proc. Am. Soc. Clin. Oncol., 12: 720, 1993.
27. DROZ, J.P., KRAMAR, A., NICHOLS C.R., et al. Second line chemotherapy with ifosfamide, cisplatin and either etoposide or vinblastine in recurrent germ cell cancer: assignment of prognostic groups. (Abst. 704). Proc. Am. Soc. Clin. Oncol. 12, 229, 1993.
28. ROSTI, G., ALBERTAZZI, L., SALVIONI, R. et al: High-dose chemotherapy supported with autologous bone marrow transplantation in germ cell tumors. A phase II study. Ann. Oncol. 10: 809-812, 1992.
29. NICHOLS, C.R., TRICOT, G., WILLIAMS, S.D., et al. Dose-intensive chemotherapy in refractory germ cell cancer - a phase I/II trial of high-dose Carboplatin and Etoposide with autologous bone marrow transplantation. J. Clin. Oncol. 7: 932-939, 1989.
30. BAJORIN, D.F., SAROSDY, M.F., PFISTER, D.G., et al: Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good risk germ cell tumors: a multiinstitutional study. J. Clin. Oncol., 11 (4): 598-606, 1993.
31. HORWICH, A. Salvage therapy for Germ Cell Tumors. Br. J. Cancer 71: 901-903, 1995.